Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partially aligned: indications for psoriatic arthritis and plaque psoriasis are supported, and ankylosing spondylitis dosing is supported, but several dosing regimens (especially plaque psoriasis and PsA 300 mg loading schedule) and multiple safety/side-effect claims are unsupported or not supported by the provided label excerpts. Mechanism of action and BMI-related dosing are also unsupported. Boxed warnings/contraindications cannot be evaluated from the supplied excerpts.
Category Scores
Accurate Statements
Cosentyx is used to treat psoriatic arthritis.
Indicated for active psoriatic arthritis in adults and pediatric patients 2 years of age and older (label section 1.2).
Cosentyx is used to treat plaque psoriasis.
Indicated for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy (label section 1.1).
For ankylosing spondylitis, Cosentyx is dosed at 150 mg every week for 5 weeks, followed by 150 mg every 4 weeks.
With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter (label section 2.6).
Some patients may require adjustments to the Cosentyx dosage based on individual response to treatment.
For active PsA or AS, consider increasing the dosage if the patient continues to have active disease (label sections 2.4 and 2.6).
Unsupported Statements
Cosentyx works by blocking the action of interleukin-17A.
Mechanism of action is not described in the provided label excerpts.
For plaque psoriasis, Cosentyx is dosed at 300 mg every week for 5 weeks, followed by 300 mg every 4 weeks.
Plaque psoriasis dosing schedule is not provided in the supplied label excerpts.
Common side effects of Cosentyx include injection site reactions.
The provided label excerpts do not contain adverse reaction/side effect details (only a 'WARNINGS AND PRECAUTIONS' heading is shown).
Common side effects of Cosentyx include upper respiratory tract infections.
The provided label excerpts do not contain adverse reaction/side effect details.
Common side effects of Cosentyx include headache.
The provided label excerpts do not contain adverse reaction/side effect details.
Patients with a higher body mass index (BMI) may require a higher dose to achieve optimal results.
BMI-related dosing guidance is not present in the supplied label excerpts.
Contradictions
Low
AI Statement
Patients with psoriatic arthritis will need 4 doses of Cosentyx per month.
Label Reference
Label sections 2.4 describe dosing at Weeks 0, 1, 2, 3, and 4 (then every 4 weeks thereafter), which implies 5 doses across the initial period rather than a blanket '4 doses per month' statement.
Low
AI Statement
Patients with ankylosing spondylitis will need 4 doses of Cosentyx per month.
Label Reference
Label section 2.6 describes dosing at Weeks 0, 1, 2, 3, and 4 (then every 4 weeks thereafter), which does not clearly support a blanket '4 doses per month' statement.
Low
AI Statement
For psoriatic arthritis, Cosentyx is dosed at 300 mg every week for 5 weeks, followed by 300 mg every 4 weeks.
Label Reference
Label section 2.4 includes dosing recommendations with a 150 mg loading/maintenance approach and a later consideration to increase to 300 mg every 4 weeks if active disease continues; the exact stated 300 mg weekly for 5 weeks schedule is not supported by the provided excerpt.
Important Omissions
FDA boxed warnings and contraindications (and other key safety sections) cannot be assessed because they were not included in the supplied label excerpts.
Importance:
Moderate
Plaque psoriasis dosing regimen and route-specific administration details are not evaluable because plaque psoriasis dosing information is not included in the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported adverse event/side-effect claims and multiple unsupported or not-fully-supported dosing statements (notably plaque psoriasis regimen and PsA 300 mg weekly schedule) reduce label alignment confidence. Boxed warnings/contraindications are not available in the provided excerpts for evaluation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several dosing regimens and all provided side-effect claims are unsupported by the supplied label excerpts; plaque psoriasis dosing and the specific PsA 300 mg weekly for 5 weeks regimen are not supported.
Suggested Improvement
Limit claims to those explicitly supported by the provided label sections: use the supported indications (1.1, 1.2), the supported AS dosing (2.6), and remove or rephrase unsupported items (interleukin-17A mechanism, plaque psoriasis dosing schedule, BMI dose claims, and all 'common side effects' statements). Provide additional label excerpts (e.g., full Dosage and Adverse Reactions, Contraindications, Warnings sections) before making safety or regimen-specific claims.